Scholar Rock appoints Dr. Jing Marantz as CMO, grants 250,000-share option award

Scholar Rock Holding Corp

Dr. Jing Marantz appointed CMO effective Nov 9, 2022; brings >20 yrs experience in neurology, oncology, rare diseases.
Base salary $465,000, annual bonus target 40% of base, and inducement stock option for 250,000 shares.
Option vests 25% on first anniversary, remainder quarterly over 3 years; subject to continuing service.
Prior roles include EVP/CBO at Krystal Biotech, SVP at Acceleron (Merck) and Alnylam; board member at Arcturus Therapeutics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Jing Marantz

Chief Medical Officer

SRRK · Scholar Rock Holding Corp

Effective: 2022-11-09
Filed: November 9, 2022, 6:59 PM ET

appointed Dr. Jing Marantz as Chief Medical Officer effective as of November 9, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Jing Marantz was appointed as Chief Medical Officer at Scholar Rock Holding Corp.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

appointed Dr. Jing Marantz as Chief Medical Officer effective as of November 9, 2022

View on SEC.gov

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001157523-22-001571

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.